

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

RECEIVED  
SECRETARY OF THE SENATE

00 FEB 14 PM 4 48

HAND DELIVERED

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name <u>Abbott Laboratories</u>			
2. Address <input type="checkbox"/> Check if different than previously reported <u>1710 Rhode Island Ave., NW, Suite 300, Washington, DC 20036</u>			
3. Principal Place of Business (if different from line 2) City: <u>Abbott Park</u> State/Zip (or Country) <u>Illinois 60064</u>			
4. Contact Name <u>Cynthia B. Sensibaugh</u>	Telephone <u>(202) 659-8924</u>	E-mail (optional) <u>cynthia.sensibaugh@abbott.com</u>	5. Senate ID #
7. Client Name <input checked="" type="checkbox"/> Self	6. House ID # <u>30001000</u>		

**TYPE OF REPORT** 8. Year 1999 Midyear (January 1-June 30)  OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇨ Termination Date \_\_\_\_\_

11. No Lobbying Activity

### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Income (nearest \$20,000)	\$10,000 or more <input checked="" type="checkbox"/> ⇨ <u>\$ 5.539 million</u> Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options. <input type="checkbox"/> Method A. Reporting amounts using LDA definitions only <input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code <input checked="" type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature \_\_\_\_\_

Printed Name and Title \_\_\_\_\_

Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

HR 3194 - Labor/HHS FY 2000 Appropriations bill - funding for state AIDS Drug Assistance Programs under the Ryan White Act

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Rosemary T. Haas (Abbott Laboratories Inc.)		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_

Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

HR 2100 - Anti-tampering Act of 1999

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Cynthia E. Sensibaugh (Abbott Laboratories, Inc.)		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_

Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

1. HR 2723, S1344 - Patients' Bill of Rights
2. S1243 - Prostate Cancer Research and Prevention Act
3. FDA related activities regarding the Food, Drug and Cosmetic Act and quality system regulation

17. House(s) of Congress and Federal agencies contacted  Check if None

House \_\_\_\_\_  
Senate \_\_\_\_\_

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
David W. Landside (Abbott Laboratories, Inc.)		<input type="checkbox"/>
Cynthia E. Sensibaugh (Abbott Laboratories, Inc.)		<input type="checkbox"/>
Rosemary T. Haas (Abbott Laboratories, Inc.)		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_

Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code LBR (one per page)

16. Specific lobbying issues

1. HR 987 - Workplace Preservation Act
2. HR 1899, S 1140 - Health Care Worker Needlestick Prevention Act

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Rosemary T. Haas (Abbott Laboratories Inc.)		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_

Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

1. HR 664, S 731 - Prescription Drug Fairness for Seniors Act of 1999
2. HR 1495, S 841 - Access to Rx Medications in Medicare Act of 1999
3. S 1895 - Medicare Preservation and Improvement Act of 1999
4. S 1480, HR 2782 - Seniors Prescription Insurance Coverage Equity Act of 1999
5. HR 2925 - Medicare Beneficiary Prescription Drug Assistance and Stop-Loss Protection Act of 1999

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
David W. Landside (Abbott Laboratories, Inc.)		<input type="checkbox"/>
Cynthia B. Sensibaugh (Abbott Laboratories, Inc.)		<input type="checkbox"/>
Rosemary T. Haas (Abbott Laboratories, Inc.)		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_

Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code M4M (cont'd) (one per page)

16. Specific lobbying issues

- 6. HR 2030, S 1626 - Medicare Patient Access to Technology Act of 1999
- 7. HR 3194 - Medicare, Medicaid and SCHIP Balanced Budget Refinement Act of 1999
- 8. NCEA's "inherent reasonableness" proposal to lower Medicare reimbursement for blood glucose test strips and enteral nutrition
- 9. Administration's FY 2000 budget proposal - Medicare provisions relating to reduction in laboratory fee schedule and imposition of beneficiary copayment for laboratory services

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
David W. Landside (Abbott Laboratories Inc.)		<input type="checkbox"/>
Cynthia B. Sensibaugh (Abbott Laboratories Inc.)		<input type="checkbox"/>
Rosemary T. Haas (Abbott Laboratories Inc.)		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_

Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific lobbying issues

1. HR 835, S 680 - permanent extension of the Research and Development Tax Credit
2. European Union proposal to eliminate the foreign sales corporation

17. House(s) of Congress and Federal agencies contacted  Check if None

House \_\_\_\_\_  
Senate \_\_\_\_\_

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
David W. Lendside (Abbott Laboratories, Inc.)		<input type="checkbox"/>
Cynthia B. Sensibaugh (Abbott Laboratories, Inc.)		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_



Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific lobbying issues

1. HR 434, S 1387 - Africa Free Trade bill
2. HR 2991, S 1619 - amends the Trade Act of 1974 to provide for periodic revision of retaliation lists or other remedial action implemented under Section 306

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
David W. Landsida (Abbott Laboratories, Inc.)		<input type="checkbox"/>
Rosemary T. Haas (Abbott Laboratories, Inc.)		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature Cynthia B. Sensibaugh Date February 14, 2000  
Printed Name and Title Cynthia B. Sensibaugh, Director, Washington Affairs